Applied Genetic Technologies, a biotech developing gene therapies for orphan eye diseases, raised $50 million by offering 4.2 million shares at $12, below its proposed $13 to $15 range. The Alachua, FL-based company originally filed to sell 3.6 million shares. Applied Genetic Technologies will list on the NASDAQ under the symbol AGTC. Applied Genetic Technologies filed confidentially on November 4, 2013. BMO Capital Markets and Wedbush PacGrow acted as lead managers on the deal.
